Drug Discovery World

SEPTEMBER 6, 2022

The fact that these benefits “may not be attainable with small molecules or even simpler biologics, as well as long periods of market exclusivity,” Scharenberg says, means that “more complicated compounds are harder to copy and require more investment to compete with making them strong continued investment targets.” . Workforce .

Therapies 130

Therapies Clinical Trials Vaccine Disease 130

Agency IQ

JULY 26, 2024

in equipment) for products that are more complex or aren’t as well-characterized, such as antibody drug conjugates or recombinant DNA products, will be considered higher risk than they would if the change was made to the production of standard, small molecule products. Any CMC changes (e.g., Comments are due September 23, 2024.

Biosimilars 40

Biosimilars Science FDA Licensing 40

The Pharma Data

DECEMBER 12, 2020

AstraZeneca has developed a broad range of technologies, initially focused on small molecules and biologics and with a growing focus in precision medicine, genomics, oligonucleotides and epigenetics. 2 EvaluatePharma, World Preview 2020, Outlook to 2026. AstraZeneca PLC. _. This announcement contains inside information.

Regulations 75

Regulations International Disease Small Molecule 75

The Pharma Data

SEPTEMBER 15, 2020

27 key programs highlighted, including assets that could potentially contribute revenue by 2025 and others in the 2026-2028 time frame. The results demonstrated that Penta immune responses were robust and noninferior to licensed meningococcal vaccines (MenB and MenACWY) in individuals 10-25 years of age, regardless of prior MenACWY exposure.

Vaccine 52

Vaccine Therapies Trials Clinical Trials 52